Gavin MacBeath, Ph.D.
Chief Scientific Officer
“I am excited to be working with exceptional scientists on disruptive technology that has the potential to deliver life-changing therapies to cancer patients.”
Gavin MacBeath is the Chief Scientific Officer at TScan Therapeutics. He has two decades of experience in academia and industry, founding companies and driving research from early-stage discovery through drug approval. Prior to joining TScan, Gavin served as the Chief Scientific Officer at Abpro, where he advanced T cell-engaging bispecific antibodies through pre-clinical development. Previously, Dr. MacBeath served as Co-founder and SVP of Discovery at Merrimack Pharmaceuticals where he advanced several biologics through IND, Phase 1, and Phase 2 clinical development. Dr. MacBeath began his career in academia, where he served as the first fellow at Harvard’s Bauer Center for Genomics Research, as an Assistant Professor and later Associate Professor in the Department of Chemistry & Chemical Biology at Harvard University, and as Lecturer and Principal Investigator at Harvard Medical School. Dr. MacBeath received his undergraduate degree from the University of Manitoba, his Ph.D. from The Scripps Research Institute, and postdoctoral training with Dr. Stuart Schreiber at Harvard University.
When he’s away from running R&D at TScan, Gavin relaxes by running marathons and ultramarathons. Among his various races, he has completed 9 Boston Marathons, as well as the iconic Leadville LT100 race (a 100-mile trail race in the high Rocky Mountains of Colorado).